Cytomegalovirus Pneumonia Not Responding to Initial Antiviral Therapy
When CMV pneumonia does not resolve with first-line antiviral monotherapy, persistent fever, cough, dyspnea, and diffuse pulmonary interstitial infiltrates indicate a need for an escalated treatment approach.
Previous Treatment & Failure Condition
Initial management of CMV pneumonia relies on monotherapy with ganciclovir or foscarnet. Escalation to this protocol is indicated when single-agent therapy, maintained for a minimum of 21 days, has not achieved resolution of all of the following:
- Fever
- Cough or dyspnea
- Diffuse pulmonary interstitial infiltrates
Next-Line Approach
When single-drug therapy has not produced the required clinical response, the evidence supports escalating to a combination of two antiviral agents, which has demonstrated superior efficacy compared to either agent used alone.
Full agent selection, dosing, sequencing, and management details are available in the structured protocol below.
References
- Data are limited on treatment failure for CMV disease other than retinitis, but the potential mechanisms and management strategies for treatment failure are likely similar to those seen in the setting of retinitis.
- Ganciclovir and foscarnet in combination appear to provide superior efficacy than either agent alone, and their combination is recommended for people whose disease does not respond to single-drug therapy or if there is continued progression or multiple reactivations of retinitis (CIII).
View source ↗